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. Achieving this will require medicines that can eliminate all three stages of Plasmodium parasite infection in humans. On page 344, Kato et al. 2 report compounds, known as bi cyclic azetidines, that display this multistage activity.
Kato and colleagues' work comes at a pivotal time. Malaria treatments rely on artemisininbased combination therapies (ACTs), which combine an artemisinin-based compound with a second antimalarial drug. The rapid efficacy and global implementation of ACTs, coupled with increased mosquito-vector control efforts, have halved malaria death rates in the past 15 years 1 . However, artemisinin resistance has emerged and is now widespread in southeast Asia 3 . This places the partner drugs under increased evolutionary selection pressure for the development of resistance. In found that selective genetic down regulation of other HSPs resulted in increased death of type 1 cells compared with type 2 cells, suggesting that type 1 cell survival depends on an intact epichaperome.
Using protein-complex analysis techniques and PU-H71 treatment, Rodina and colleagues investigated the epichaperome in different types of cancer cell. The epichaperome was detected in 60-70% of cell lines from breast, pancreatic, lung, leukaemia and other cancers, indicating the potential clinical relevance of this protein complex as a therapeutic target. Strikingly, the epichaperome was not restricted to a particular cancer subset characterized by specific gene or protein expression. Type 1 cells also had high levels of the cancer-associated MYC protein. When MYC was down regulated, the epichaperome disappeared, whereas overexpressing MYC in type 2 cells induced epichaperome formation. Thus, MYC is an important regulator of epichaperome assembly.
Treatments for cancer require a target that is present in most cancer cells but absent in normal cells. Rodina and colleagues' finding that type 1 cancer cells contain HSP90 in the epichaperome, but that normal cells have HSP90 mainly in a non-complexed form, suggests that the epichaperome might be a clinical target.
Despite the encouraging results, the authors found considerable differences in dependence on epichaperome formation, both between tumour types and between tumour cells of the same type (for example, breast cancer), which might allow the emergence of treatment-resistant variants. Moreover, in many cancers, such as breast cancer, the metastatic migration of cancer cells to other locations in the body is the main cause of death, and metastatic cells may differ from the initial primary tumours. It remains to be determined to what extent metastatic cells depend on epichaperome formation, and how such cells might respond to drugs that target the complex.
However, obtaining metastatic tissue from a patient by needle biopsy is a problem because of the procedure's invasive nature, and some lesions (for example, in the lung, bone and brain) are difficult to access. 'Liquid biopsy' of circulating tumour cells in the peripheral blood might be an alternative feasible strategy for assessing the epichaperome in metastatic cells. Analysis of circulating tumour cells or tumour cells that have migrated to the bone marrow in people in the early stages of cancer might also provide information on potential precursors of metastases 2, 3 . Rodina and colleagues' findings could have broader implications. Many cellular programs consist of signalling pathways that rely on a large number of proteins, and these might form stable complexes in a similar way to how the epichaperome forms. For example, the chaperone machinery in a cellular organelle 4 , and the activity of endoplasmic reticulum chaperones under conditions of cellular stress strongly affects cancer-cell survival 5 . Moreover, cancerassociated ErbB receptors might assemble into higher-order receptor complexes 6 . Thus, the discovery of other large, cancer-specific protein complexes might open further avenues of investigation for understanding cancer biology, with potential implications for the design of new strategies for cancer therapy. ■ Cambodia, the ACT of dihydroartemisinin and piperaquine is failing rapidly because of resistance to both compounds 4 . Historical precedents suggest that resistance to first-line ACT agents might take hold in Africa next. There is thus an urgent need to develop more medicines.
The first stage of Plasmodium infection in humans is an asymptomatic infection of the liver; the second stage occurs when asexual parasites cause disease by infecting red blood cells; and at the third stage, parasites form sexual-stage gametocytes in red blood cells that, once mature, can be transmitted to Anopheles mosquitoes (Fig. 1) . To identify potential multistage inhibitors, Kato et al. first carried out a high-throughput screen using in vitro cultures of asexual blood-stage parasites of Plasmodium falciparum, the most lethal of the human malarial parasites.
The authors tested a library of approximately 100,000 compounds to search for parasite growth inhibitors. These compounds were produced using a technique known as diversity-oriented synthesis, in which chemical structures are built and coupled to generate molecules in a process inspired by the diversity and structural complexity of naturally occurring compounds 5 . Kato and colleagues then tested their inhibitory compounds against asexual blood-stage parasites from a panel of parasite strains resistant to known antimalarial agents, and extended the assays to liver and gametocyte-stage parasites.
The authors' screens identified several series of 'hits' that acted on known malarialdrug-target proteins, such as P. falciparum ATP4, PI4K and DHODH (ref. 6) , as well as a wealth of other hits (including bicyclic azetidines) that have potentially new modes of action. The hits are documented at the Malaria Therapeutics Response Portal website (http:// portals.broadinstitute.org/mtrp), which is a valuable resource for future antimalarial-drug discovery and development efforts.
By selecting for drug resistance in cultured parasites and applying whole-genome DNAsequence analysis to identify genetic changes, Kato et al. obtained evidence that the bicyclic azetidines target an enzyme termed cytosolic P. falci parum phenylalanyl-tRNA synthetase (Pf PheRS). This finding was confirmed in biochemical assays demonstrating chemical inhibition of the enzyme. PheRS acts on transfer-RNA molecules, enabling them to deliver the amino acid phenylalanine to nascent proteins during the vital cellular process of messenger-RNA translation and protein synthesis. tRNA synthetase enzymes have emerged in recent years as a promising class of antimalarial target 7 . Kato et al. tested their lead bicyclic azetidine compound BRD7929 in mouse models of malarial infection using either P. falciparum or the rodent parasite, Plasmodium berghei. The authors found that a single, low dose of BRD7929 was sufficient to eliminate infections at the liver or asexual blood stages, affording complete cure. Transmission-blocking activity at the gametocyte stage was also observed at drug concentrations that achieved singledose cures of asexual blood-stage infections. If similar efficacy could be achieved in treating human infections, it would change the landscape of disease treatment and control by providing a powerful tool for malaria elimination 6 . The inspired decision by Kato and colleagues to screen natural-product-like compounds amenable to synthesis was one key to the study's success. The other notable factor was the remarkable coordination between the various collaborating research laboratories. This enabled testing of Pf PheRS inhibitors throughout the parasitic life cycle, as well as chemical optimization and pharmacological evaluation of the compounds that was achieved by assessing the relationship between their structures and activities. Of course, there is no guarantee that bicyclic azetidines will ultimately yield a licensed medicine with the desired single-dose cure, prevention and transmission-blocking properties.
BRD7929 displayed good oral bioavailability (the amount of drug that reaches the bloodstream after oral ingestion) and other promising pharmacological properties, including a long half-life -approximately 32 hours in mice. Yet it remains possible that this compound might encounter setbacks during further testing, such as toxicological issues or problems in drug selectivity for the parasite enzyme over its human counterpart. The establishment by Kato et al. of a functional screen that uses Pf PheRS provides opportunities to identify alternative chemical scaffolds to bicyclic azetidines, if necessary.
Given the constant concern of anti malarial drug resistance 8 , Kato and colleagues tested their compound for resistance development. They found that bicyclic azetidine treatment selects for resistance with a frequency of greater than 1 per 10 9 parasites, which compares favourably with other preclinical drug candidates 9, 10 . To place this in context, an infected, symptomatic individual can harbour up to 10 12 parasites 6 . Therefore, resistance might emerge in settings in which the disease is endemic, although its ability to become established and spread is tempered by many factors, including host immunity and parasite fitness. Resistance concerns can be mitigated by combining PheRS inhibitors with pharmacologically matched inhibitors that have a different mode of action.
Future studies will also be needed to evaluate whether PheRS inhibitors can effectively eliminate another human malaria parasite, Plasmodium vivax, which has a dormant stage of liver infection. These dormant parasites can reinitiate growth and cause relapse months or even years after the primary infection. The need for a drug to target dormant P. vivax liver infections is particularly acute because primaquine, the only licensed drug treatment for this form of the disease, can be highly toxic to people with certain types of deficiency for the enzyme glucose-6-phosphate dehydrogenase -a common genetic trait 6 . Single-dose malaria cures, combined with 2 identified the compound BRD7929, which, when tested against the human parasite Plasmodium falciparum or the rodent species Plasmodium berghei in mouse models, provided a single-dose cure and was able to prevent malaria and block onward transmission of the parasite. Me, methyl group. safe and effective prevention and transmission-blocking measures, would be a tremendous boon to afflicted populations, whose socio-economic challenges are exacerbated by this debilitating disease. The world would be a healthier community of nations if this goal were to be achieved. The current study demonstrates the power of coordinating the multifaceted research activities required to achieve such a goal. ■ 
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